Choosing pharmacological or mechanical thromboprophylaxis, renal and obesity dosing, and who needs stress ulcer prophylaxis after REVISE.
At the bedside
- 1
Assess bleeding risk
Active bleeding, platelets < 50 × 10⁹/L, recent neurosurgery/intracranial haemorrhage, severe coagulopathy, planned neuraxial procedure.
- 2
No contraindication
LMWH: enoxaparin 40 mg SC daily (dalteparin 5,000 units daily is an alternative). CrCl < 30 mL/min: enoxaparin 30 mg daily or UFH 5,000 units SC every 8-12 h.
- 3
Contraindication
Intermittent pneumatic compression; start pharmacological prophylaxis as soon as bleeding risk allows. Adding IPC to pharmacological prophylaxis gives no extra benefit (PREVENT).
- 4
Special cases
Obesity: higher doses (see drug); trauma, burns, spinal cord injury: earlier and more intensive prophylaxis per trauma guidelines; HIT: non-heparin anticoagulant.
- 5
SUP: who
Invasive mechanical ventilation, coagulopathy, shock, chronic liver disease (high risk). Not routinely for low-risk patients.
- 6
SUP: what
Pantoprazole 40 mg IV/enteral daily (or H2RA); REVISE showed fewer clinically important UGI bleeds in ventilated patients with no mortality difference.
- 7
Stop
Stop SUP when the risk factor resolves (extubation, shock resolved); do not continue at discharge.
VTE prophylaxis
Enoxaparin
- Dose
- 40 mg once daily
- Worked example
- 70 kg, CrCl 80 mL/min: enoxaparin 40 mg SC at 18:00 daily. If CrCl falls to 25 mL/min: 30 mg daily or switch to UFH 5,000 units SC every 12 h.
Range: 30 mg daily (CrCl < 30) to 40 mg every 12 h (BMI ≥ 40).
Open Creatinine clearance (Cockcroft-Gault)VTE prophylaxis in severe renal impairment
Unfractionated heparin (subcutaneous)
- Dose
- 5,000 units every 8-12 h
Stress ulcer prophylaxis (high risk)
Pantoprazole
- Dose
- 40 mg once daily
- Worked example
- Ventilated 70 kg patient: pantoprazole 40 mg IV daily; stop after extubation if no other indication.
Stress ulcer prophylaxis (alternative)
Famotidine
- Dose
- 20 mg every 12 h
Once daily if CrCl < 50 mL/min.
Stress ulcer prophylaxis decision
| Risk group | Examples | SUP |
|---|---|---|
| High | Invasive ventilation; coagulopathy (platelets < 50 × 10⁹/L, INR > 1.5); shock; chronic liver disease | Suggest PPI or H2RA |
| Low | Non-ventilated, haemodynamically stable, no coagulopathy | Not routinely |
| Already on therapeutic indication | Recent peptic ulcer, Barrett's, dual antiplatelets with GI risk | Continue home PPI |
Based on the 2021 clinical practice guideline and REVISE 2024.
Calculators for this topic
Pathophysiology
Immobility, venous injury from lines, inflammation and hypercoagulability (Virchow's triad) drive ICU VTE. Stress ulceration results from splanchnic hypoperfusion, mucosal ischaemia and impaired bicarbonate secretion; acid suppression reduces bleeding but may increase pneumonia and C. difficile.
Evidence
- ASH 2018 guideline: LMWH preferred; pharmacological over mechanical [Schünemann 2018].
- PREVENT (2,003 patients): adjunctive IPC did not reduce proximal DVT [Arabi 2019].
- SUP-ICU (3,298): pantoprazole did not change 90-day mortality [Krag 2018].
- REVISE (4,821 ventilated patients): pantoprazole reduced clinically important UGI bleeding (1.0% vs 3.5%) without mortality difference [Cook 2024].
- 2021 SUP guideline: suggest SUP in high-risk patients only [Ye 2021].
Controversies
- SUP in the sickest patients (SUP-ICU subgroup signal of harm in high severity, not confirmed by REVISE); anti-Xa guided dosing in obesity and renal failure.
🇮🇳 India notes
- Enoxaparin biosimilars are widely available and affordable; IPC devices are limited in many ICUs - prioritise them for patients with contraindications.
- Stress ulcer prophylaxis is often over-prescribed on general wards in India and continued at discharge; use the ICU daily checklist to stop it.
References
Test yourself
Module quiz · score 70% to complete the module
Educational reference for trained clinicians. Check doses against your hospital protocol and the patient in front of you.

